CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clorox Co (CLX) is not a strong buy at this time for a beginner investor with a long-term focus. The stock faces significant challenges, including weak financial guidance, cost pressures, and a cautious sentiment from analysts and Congress members. While there are some leadership changes aimed at growth, the current headwinds outweigh the potential benefits. It is better to hold off on investing until there is clearer evidence of a turnaround.
The technical indicators for CLX are neutral. The MACD histogram is positive but contracting, the RSI is at 50.739 (neutral zone), and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 95.841, with resistance at 99.884 and support at 91.798.
Clorox has streamlined its leadership structure, appointing a COO and Chief Growth & Strategy Officer, which could enhance growth in health and hygiene. The company is also reshaping its portfolio, potentially unlocking future growth opportunities.
Clorox faces significant challenges, including weaker FY26 guidance, cost pressures from oil and gas, soft consumer trends, and headwinds from the Middle East conflict. Analysts have lowered price targets and ratings, and Congress members have shown a cautious attitude with two recent sale transactions.
No detailed financial data is available for the latest quarter. However, the company reported a slight EPS beat for Q3 but issued weaker FY26 guidance, citing multiple challenges, including cost pressures and delays in organic sales improvement.
Analysts have a predominantly negative outlook on CLX. Multiple firms, including Goldman Sachs, Morgan Stanley, and Barclays, have lowered price targets and ratings, citing cost pressures, weak sales trends, and limited visibility into medium-term earnings. The consensus sentiment is cautious to negative.
